Image

North America Obsessive-Compulsive Disorder (OCD) Drugs Market – Industry Trends and Forecast to 2028

Pharmaceutical

Image

North America Obsessive-Compulsive Disorder (OCD) Drugs Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Aug 2021
  • North America
  • 350 Pages
  • No of Tables: 98
  • No of Figures: 47

North America Obsessive-Compulsive Disorder (OCD) Drugs Market, By Severity (Mild to Moderate, Moderate to Severe), By Sub-Type (Contamination Obsessions with Washing/Cleaning Compulsion, Harm Obsessions With Checking Compulsions, Obsessions Without Visible Compulsions, Symmetry Obsessions with ordering, arranging and counting compulsions, hoarding, others), By Drugs (Antidepressants, Antipsychotics, NMDA Blocker, Others), By Route of Administration (Oral, Parenteral), By Population type (Pediatrics, Adults), By End User (Hospitals, specialty Clinics, Home healthcare, others), By Distribution Channel (Hospital pharmacy, Retail Pharmacy, Online Pharmacy, Others) By Country (U.S., Canada, Mexico).

North America Obsessive-Compulsive Disorder (OCD) Drugs Market Market Analysis and Insights: North America Obsessive-Compulsive Disorder (OCD) Drugs Market

North America Obsessive-Compulsive Disorder (OCD) Drugs Market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.0% in the forecast period of 2021 to 2028 and is expected to reach USD 427.45 million by 2028. The increase in the cases of prevalence rate of infectious diseases among population across the globe and changes in lifestyle and environmental stress among people are the major drivers which propelled the demand of the market in the forecast period.

Obsessive-compulsive disorder (OCD) refers to an anxiety disorder characterized by unreasonable and uncontrollable thoughts and fears leading an individual to perform repetitive behaviours. Obsessive-compulsive disorder is a disorder known to compel a person to get stuck on a particular thought or fear. The developments in the treatment, therapies and novel treatment, and advancements in the anti-anxiety, antipsychotic and antidepressant drugs is expected to provide various other opportunities in the OCD drugs market. However, patent expiry of the patented drugs and introduction of generic version of branded drugs are factors expected to restraint the market growth in the forecast period.

The OCD drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Obsessive-Compulsive Disorder (OCD) Drugs Market North America Obsessive-Compulsive Disorder (OCD) Drugs Market Scope and Market Size

Obsessive-Compulsive Disorder (OCD) Drugs Market is segmented on the basis of severity, subtypes, drugs, route of administration, population, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

  • On the basis of severity, the North America obsessive compulsive disorder (OCD) drugs market is segmented into mild to moderate and moderate to severe. In 2021, the moderate to severe segment is dominating the North America obsessive obsessive-compulsive disorder (OCD) drugs market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe are predicted to dominate the market.
  • On the basis of subtype, the North America obsessive compulsive disorder (OCD) drugs market is segmented into contamination obsessions with washing/cleaning compulsion, harm obsessions with checking compulsions, obsessions without visible compulsions, symmetry obsessions with ordering, arranging, and counting compulsions, hoarding and others. In 2021, contamination obsessions with washing/cleaning compulsion is are dominating the North America obsessive obsessive-compulsive disorder drug market due to developments in the treatment, therapies, and introduction of novel treatments are predicted to dominate the market.
  • On the basis of drugs, the North America obsessive compulsive disorder (OCD) drugs market is segmented into antidepressants, antipsychotics, NMDA blocker, and others. Antidepressants is further segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAS), and others. SSRIs is further segmented into fluvoxamine, fluoxetine, paroxetine, sertraline, and others. SNRIs is further segmented into duloxetine, venlafaxine and others. TCAS is further segmented into clomipramine, amitriptyline, imipramine and others. Antipsychotics is further segmented into risperidone, haloperidol, quetiapine, olanzapine, aripiprazole and others. NMDA blocker is further segmented into ketamine, memantine, and others. In 2021, the antidepressants segment is dominating the North America obsessive obsessive-compulsive disorder drug market due to advancements in the anti-anxiety, antipsychotic and antidepressant drugs, and the robust pipelines for the development of newer treatment are predicted to dominate the market.
  • On the basis of route of administration, the North America obsessive compulsive disorder (OCD) drugs market is segmented into oral and parenteral. Oral is further segmented into tablet, capsules and solution. In 2021, the oral segment is dominating the North America obsessive obsessive-compulsive disorder (OCD) drugs market due to novel treatment, and advancements in therapies are predicted to dominate the market.
  • On the basis of population, the North America obsessive compulsive disorder (OCD) drugs market is segmented into pediatrics and adults. In 2021, the adults segment is dominating the North America obsessive obsessive-compulsive disorder drug market due to research and development to enhance bioavailability, pharmacology, safety, and dosage parameters is are predicted to dominate the market. 
  • On the basis of end user, the North America obsessive compulsive disorder (OCD) drugs market is segmented into hospitals, specialty clinics, home healthcare, and others. In 2021, the hospitals segment is dominating the North America obsessive obsessive-compulsive disorder drug market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe is predicted to dominate the market.
  • On the basis of distribution channels, the North America obsessive compulsive disorder (OCD) drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is dominating the North America obsessive compulsive disorder drug market due to novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs are predicted to dominate the market.  
  • In North America, U.S. is the dominant region due to growing position in OCD drug market with novel drug products and strong brand name of drug product.

Obsessive-Compulsive Disorder (OCD) Drugs Market Country Level Analysis

The OCD drugs market is analyzed and market size information is provided on the basis of severity, subtypes, drugs, route of administration, population, end user and distribution channel.

The countries covered in the OCD drugs market report are U.S., Canada, and Mexico.  

Oral segment in North America region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of rise in clinical trials and increasing generic approvals.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Strategic initiatives by market players and rise in awareness among people with respect to the disorder are boosting the Market Growth of OCD drugs products.

Obsessive-Compulsive Disorder (OCD) Drugs market also provides you with detailed market analysis for every country growth in OCD products industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2018.

Competitive Landscape and OCD Market Share Analysis

OCD drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to OCD drugs market.

The major companies which are dealing in the Obsessive-Compulsive Disorder (OCD) drugs are Lannett, H. LUNDBECK A/S, Teva Pharmaceutical industries Ltd. (a subsidiary of Teva Pharmaceutical Industries Ltd.), GlaxoSmithKline plc., Pfizer Inc., Mallinckrodt, Sebela Pharmaceuticals, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Lupin Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories Ltd., , Wockhardt, Alvogen, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Par Pharmaceutical, Apotex Inc., Abbott, Eli Lilly and Company, Viatria Inc., among others.

Many product launch and agreement are also initiated by the companies’ worldwide, which are also accelerating the OCD drugs market.

For instance,

  • In February 2021, Lannett announced that it has added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of companies (HEC). Lannett will fund most of the clinical development requirements, while HEC continues to develop the product and related manufacturing infrastructure. Lannett and HEC will share in the profits of the venture.  
  • In January 2021, Lundbeck and Better Energy ensures the construction of a new solar park. Lundbeck entered a 7-year power purchase agreement (PPA) with the company Better Energy to ensure a 100 percent renewable electricity consumption. As a result of the deal, Better Energy will build a new solar park and bring more new renewable electricity into the Danish grid.
  • In May 2021, Teva Pharmaceuticals (a subsidiary of Teva Pharmaceutical Industries Ltd.) announced its launch of the first available generic version, in the U.S., of THIOLA® (tiopronin) tablets, indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine (kidney) stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the OCD drugs market which also provides the benefit for organization to improve their offering for OCD drugs products.  


SKU-

LIST OF TABLES

TABLE 1 BELOW MENTIONED ARE THE COST OF OCD DRUGS, AVAILABLE IN DIFFERENT DOSAGE FORMS SUCH AS A TABLET, CAPSULE, PARENTAL, AND STRENGTHS USED NORTH AMERICALY TO TREAT OBSESSIVE-COMPULSIVE DISORDER.

TABLE 2 DRUGS UNDER INVESTIGATIONS FOR OCD

TABLE 3 R&D COST BY KEY MARKET PLAYERS (USD MILLIONS) (2020)

TABLE 4 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA MODERATE TO SEVERE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA MILD TO MODERATE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA HARM OBSESSIONS WITH CHECKING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA OBSESSIONS WITHOUT VISIBLE COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA HOARDING IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA PARENTERAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA ADULTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA PEDIATRICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA HOSPITALS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA SPECIALTY CLINICS IN OBSESSIVE-COMPULSIVE (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA HOME HEALTHCARE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA HOSPITAL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA RETAIL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA ONLINE PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 57 U.S. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 58 U.S. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)

TABLE 59 U.S. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 60 U.S. ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 61 U.S. SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 62 U.S. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 63 U.S. TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 64 U.S. ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 65 U.S. NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 66 U.S. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 67 U.S. ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 68 U.S. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 69 U.S. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 70 U.S. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 71 CANADA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 72 CANADA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)

TABLE 73 CANADA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 74 CANADA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 75 CANADA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 76 CANADA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 77 CANADA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 78 CANADA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 79 CANADA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 80 CANADA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 81 CANADA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 82 CANADA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 83 CANADA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 84 CANADA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 85 MEXICO OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 86 MEXICO OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)

TABLE 87 MEXICO OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 88 MEXICO ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 89 MEXICO SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 90 MEXICO SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 91 MEXICO TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 92 MEXICO ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 93 MEXICO NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)

TABLE 94 MEXICO OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 95 MEXICO ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 MEXICO OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 97 MEXICO OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 98 MEXICO OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials